Skip to main content
. 2014 Jan 1;16(8):1035–1036. doi: 10.1093/neuonc/nou120

Table 1.

Key conclusions

  • There is no safe dose of WBRT for the brain.

  • Reduced-dose WBRT will not be more effective than standard-dose WBRT.

  • Intensifying chemotherapy up-front will not make WBRT for consolidation more effective.

  • Intensifying chemotherapy up-front will not make WBRT for consolidation safer.

  • PCNSL needs to be “cured” at initial diagnosis, not at recurrence: WBRT at recurrence remains an option, but probably does not prolong survival.